Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.

The journal of pathology. Clinical research - 1 Jul 2022

Higashi Morihiro, Momose Shuji, Takayanagi Natsuko, Tanaka Yuka, Anan Tomoe, Yamashita Takahisa, Kikuchi Jun, Tokuhira Michihide, Kizaki Masahiro, Tamaru Jun-Ichi

Abstract excerpt

The tumor microenvironment (TME) is a critical regulator of the development of malignant lymphoma. Therapeutics targeting the TME, especially immune checkpoint molecules, are changing the treatment strategy for lymphoma. However, the overall response to these therapeutics for diffuse large B-cell lymphoma (DLBCL) is modest and new targets of immunotherapy are needed. To find critical immune checkpoint molecules...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD24 Antigen
Share to Lymphoma, Large B-Cell, Diffuse

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Prognosis

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35289116
DOI: 10.1002/cjp2.266
PMCID: PMC9161324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.PMID 35289116Read ↗

Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapySemantic proximity Read ↗

Surprising magic of CD24 beyond cancerSemantic proximity Read ↗

Genomic alterations underlying immune privilege in malignant lymphomasSemantic proximity Read ↗

CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironmentSemantic proximity Read ↗

Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomasSemantic proximity Read ↗

Identification of the novel exhausted T cell CD8 + markers in breast cancerSemantic proximity Read ↗

A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapySemantic proximity Read ↗

Identification and validation of M2 macrophage-related differential genes in DLBCLSemantic proximity Read ↗

Polymorphisms and overexpression of immune checkpoints PD-1, PD-L1, and CTLA-4 in DLBCL: biomarker insights from a case-control study.Semantic proximity Read ↗

Tumoral immune microenvironment profiling in B-cell non-Hodgkin lymphoma stratifies patients in different prognostic groups.Semantic proximity Read ↗

Genome-wide Screens Identify Lineage- and Tumor Specific-Genes Modulating MHC-I and MHC-II Immunosurveillance in Human LymphomasSemantic proximity Read ↗

A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of Diffuse Large B-cell LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.